Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

739P - Patient preference for subcutaneous nivolumab (NIVO) with/without recombinant human hyaluronidase PH20 (rHuPH20) vs intravenous NIVO: An exploratory analysis of a phase I/II pharmacokinetic multi-tumor study

Date

10 Sep 2022

Session

Poster session 13

Topics

Immunotherapy

Tumour Site

Presenters

Sara Lonardi

Citation

Annals of Oncology (2022) 33 (suppl_7): S331-S355. 10.1016/annonc/annonc1058

Authors

S. Lonardi1, B.M. Bennett2, M. Dixon3

Author affiliations

  • 1 Medical Oncology 3, Veneto Institute of Oncology IOV-IRCSS, 35128 - Padova/IT
  • 2 Worldwide Heor, Bristol Myers Squibb, UB8 1DH - Uxbridge/GB
  • 3 Worldwide Heor, Bristol Myers Squibb, 08640 - Princeton, NJ/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 739P

Background

Subcutaneous (SC) NIVO co-formulated with rHuPH20 may benefit patients (pts), healthcare practitioners (HCPs), and healthcare resource utilization. In the phase 1/2 international multi-tumor CheckMate 8KX study, the pharmacokinetics and exposures of SC NIVO + rHuPH20 were characterized across multiple doses and treatment was well tolerated. Here, we present pt preference for SC vs intravenous (IV) NIVO.

Methods

Pts with advanced/metastatic tumors across approved NIVO monotherapy indications (and hepatocellular carcinoma) were enrolled. Pts in part A received 1 cycle (C) of NIVO SC 720 mg + rHuPH20. In part B C1, the first 10 pts received NIVO SC 960 mg + rHuPH20 and the next 35 were randomized 1:1 to NIVO SC 720 mg or NIVO SC 960 mg. From C2, pts in parts A and B received NIVO IV 480 mg every 4 weeks (Q4W) and some transitioned to part C, 1200 mg NIVO SC + rHuPH20 Q4W. Pts in part D received NIVO SC 1200 mg + rHuPH20 Q4W. An 8-item pt experience and preference questionnaire (PEPQ) was administered by site interview immediately after NIVO on C1 day (D)1 and C2D1 in part A and B, and C1D1 of part C and D.

Results

190 PEPQ responses were received from 103 pts. Baseline characteristics were well balanced. Across parts A-C, most pts preferred SC vs IV injection (21%-71% vs 4%-28%) and pts on all regimens (including part D) were very satisfied with SC injection (78%-100%). On a scale of 0 to 10 (no to worst pain/discomfort), pts reported minimal pain/discomfort associated with SC injection (mean [SD] score: part A, C1D1 0.6 [0.7], C2D1 0.3 [0.5]; part B [across all dose regimens], C1D1 0.1-0.3 [0.2-0.5], C2D1 0-0.3 [0-0.9]; part C, 1 [0.8]; part D, 1.3 [1.6]). Overall, 90%-100% pts were not bothered by duration of SC administration; 27%-80% said NIVO injection took less time than expected, 20%-64% an acceptable time, or 5%-14% longer than expected. Most pts reported no negative impact on time available to talk to a HCP (86%-100%) or interact/socialize with non-HCPs (86%-100%).

Conclusions

Overall, fewer pts preferred IV vs SC NIVO; most pts were very satisfied and reported minimal pain/discomfort associated with SC injection in this prespecified exploratory analysis.

Clinical trial identification

NCT03656718.

Editorial acknowledgement

Professional medical writing assistance was provided by Russell Craddock, PhD, of Parexel, and was funded by Bristol Myers Squibb.

Legal entity responsible for the study

Bristol Myers Squibb.

Funding

Bristol Myers Squibb.

Disclosure

S. Lonardi: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Incyte, Lilly, Merck Serono, MSD, Servier; Financial Interests, Personal, Invited Speaker: Pierre-Fabre; Financial Interests, Institutional, Coordinating PI: Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Lilly, Merck Serono, Roche. B.M. Bennett: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. M. Dixon: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.